BIOPHARMX CORPORATION (NYSEAMERICAN: BPMX) Files An 8-K Results of Operations and Financial Condition

BIOPHARMX CORPORATION (NYSEAMERICAN: BPMX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition

Story continues below

On December 6, 2018, BioPharmX Corporation (the “Company”) issued a press release announcing its financial results and certain other information for the quarter ended October 31, 2018. A copy of the press release is attached as Exhibit99.1 to this Current Report on Form8-K.

The information in this Item 2.02, including Exhibit99.1 to this Current Report on Form8‑K, shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit99.1 shall not be incorporated by reference into any registration statement or other document filed by the Company with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form8‑K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form8‑K generally), except as shall be expressly set forth by specific reference in such filing.

Item 2.02 Financial Statements and Exhibits

(d)


BioPharmX Corp Exhibit
EX-99.1 2 bpmx-20181206ex9915f6387.htm EX-99.1 BPMX Exh 991_12718  Exhibit 99.1   BioPharmX Reports Third Quarter 2019 Financial Results MENLO PARK,…
To view the full exhibit click here

An ad to help with our costs